Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Even better kinase inhibitors for chronic myeloid leukemia.

Sawyers CL.

N Engl J Med. 2010 Jun 17;362(24):2314-5. doi: 10.1056/NEJMe1004430. Epub 2010 Jun 5. No abstract available.

PMID:
20525994
2.

[Molecular targeting therapy for chronic myeloid leukemia].

Kimura S.

Rinsho Ketsueki. 2007 Jan;48(1):46-55. Review. Japanese. No abstract available.

PMID:
17313076
3.

[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].

Miura M, Takahashi N.

Rinsho Ketsueki. 2013 Oct;54(10):1720-9. Review. Japanese. No abstract available.

PMID:
24064822
4.

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.

Swords R, Alvarado Y, Cortes J, Giles FJ.

Curr Hematol Malig Rep. 2007 May;2(2):83-8. doi: 10.1007/s11899-007-0012-4. Review.

PMID:
20425355
5.

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

White DL, Hughes TP.

Curr Hematol Malig Rep. 2011 Jun;6(2):88-95. doi: 10.1007/s11899-011-0087-9. Review.

PMID:
21448598
6.
7.

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.

Zonder JA, Schiffer CA.

Curr Hematol Malig Rep. 2006 Sep;1(3):141-51. doi: 10.1007/s11899-996-0002-y. Review.

PMID:
20425345
8.

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

Schiffer CA.

N Engl J Med. 2007 Jul 19;357(3):258-65. Review. No abstract available.

PMID:
17634461
9.

Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.

Radich JP.

Cancer. 2012 Jan 15;118(2):300-11. doi: 10.1002/cncr.26280. Epub 2011 Jun 29. Review.

10.

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.

Jabbour E, Cortes J, Kantarjian H.

Expert Opin Investig Drugs. 2007 May;16(5):679-87. Review. Erratum in: Expert Opin Investig Drugs. 2007 Jul;16(7):1135.

PMID:
17461740
11.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
12.

Initial treatment for patients with CML.

Goldman JM.

Hematology Am Soc Hematol Educ Program. 2009:453-60. doi: 10.1182/asheducation-2009.1.453. Review.

PMID:
20008231
13.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

14.

[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].

Thomas X.

Bull Cancer. 2007 Oct;94(10):871-80. Review. French.

PMID:
17964981
15.

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

PMID:
18401881
16.

[Development of ABL tyrosine kinase inhibitors].

Kimura S.

Rinsho Ketsueki. 2010 Aug;51(8):597-604. Review. Japanese. No abstract available.

PMID:
20805664
17.

[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 4. Diagnosis and treatment of chronic myeloid leukemia].

Kimura S.

Nihon Naika Gakkai Zasshi. 2013 Jul 10;102(7):1712-9. Review. Japanese. No abstract available.

PMID:
23947233
Items per page

Supplemental Content

Write to the Help Desk